Im­mu­nic touts pos­i­tive da­ta in main­te­nance phase of failed PhII tri­al, pulls back on an­oth­er as­set

A New York biotech is now say­ing it has pos­i­tive main­te­nance da­ta from a Phase II tri­al, more than 10 months af­ter re­port­ing the orig­i­nal tri­al in mod­er­ate-to-se­vere ul­cer­a­tive col­i­tis had failed. Im­mu­nic is al­so pulling back on a pso­ri­a­sis and cas­tra­tion-re­sis­tant prostate can­cer pro­gram.

Im­mu­nic re­port­ed Wednes­day that it saw an in­crease in clin­i­cal re­mis­sion af­ter 50 weeks com­pared to place­bo. Cit­ing an ex­plorato­ry analy­sis, of the 26 pa­tients with a 30mg dose of the can­di­date, vid­ofludimus cal­ci­um, 16, or 61.5%, re­port­ed clin­i­cal re­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER